RTP Mobile Logo
Oncology Today with Dr Neil Love: Key Presentations on Non-Hodgkin and Hodgkin Lymphomas from the 2020 ASH Annual Meeting — Issue 2 (Audio Program)
Released April 2021

Featuring an interview with Dr Laurie H Sehn. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

    LEARNING OBJECTIVES

    • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma to determine the current and/or potential utility of each in clinical practice.
    • Consider current research findings and clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma.
    • Understand recently presented clinical trial results informing the selection of available therapeutic agents in the nonresearch care of patients with newly diagnosed and relapsed/refractory Hodgkin lymphoma.
    • Appreciate how emerging research data affect the best-practice management of peripheral T-cell lymphoma.
    • Recall new data with agents and strategies currently under investigation for various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and her spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Laurie H Sehn, MD, MPH
    Chair, Lymphoma Tumour Group
    BC Cancer Centre for Lymphoid Cancer
    Clinical Professor of Medicine
    Division of Medical Oncology
    University of British Columbia
    Associate Editor, Blood
    Vancouver, British Columbia, Canada

    Advisory Committee and Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lundbeck, Merck, MorphoSys, Novartis, Pfizer Inc, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Seagen Inc, Takeda Oncology, Teva Oncology, Verastem Inc; Contracted Research: Teva Oncology.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Epizyme Inc, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics Inc, Kite, A Gilead Company, Novartis, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seagen Inc.

    Release date: April 2021
    Expiration date: April 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):